ArticleScientific reports2025

Low serum neopterin early indicates durable benefits of atezolizumab and pembrolizumab therapy in advanced lung cancer.

Anna Siemiątkowska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.